JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NEUROCRINE BIOSCIENCES INC
Financial Performance:
- Commercial portfolio annualizing at approximately $4.5 billion in sales, with Ingresa contributing ~$800 million (15% YoY growth, double-digit volume) and Chronicity contributing ~$850 million.
- Approximately 30% of total revenue now derived from medicines other than Ingresa, marking a significant shift from a single-product model.
- Chronicity treats ~15% of the ~20,000 patient Congenital Adrenal Hyperplasia (CAH) market.
- Net price impact for Ingresa in 2027/2028 expected to be single to mid-single digits due to IRA-related concessions, but volume growth is double-digit, resulting in net revenue growth.
- No revenue cliff anticipated post-2029 IRA price negotiations; management forecasts a "divot" followed by sustained growth, leveraging a small biotech exemption (25%–34% discount off non-FAMP).
Guidance and Future Outlook:
- 2027 identified as the most critical catalyst year with multiple Phase 3 readouts (Osevamator/MDD, Direclidine/Schizophrenia, Osvampitor/OSA) and potential commercialization of Vicat XR for Prader-Willi syndrome.
- Pipeline productivity at record levels with six new Phase 1 and five new Phase 2 starts this year.
- Ingresa Intellectual Property (IP) protection extends to 2038.
- Long-term strategy involves transitioning to a "one-stop shopping" model with next-generation oral VMAT2 inhibitors followed by Long-Acting Injectables (LAIs).
- Chronicity expects to maintain market leadership and growth through upstream HPA axis control, differentiating from potential competitors like Vertex.
Business Segments and Product Lines:
- Ingresa (VMAT2): Focus remains on expanding market share in Tardive Dyskinesia (TD) driven by growing antipsychotic prescription volume (~3% annual growth); addressing 15%–20% market share held by LAI competitors by developing next-gen LAIs.
- Chronicity: Currently 2 years into launch for CAH; unique mechanism reduces ACTH and androgens, allowing glucocorticoid dose reduction; pursuing pediatric expansion down to months-old infants.
- Vicat XR: Launched for Prader-Willi syndrome; projected to become a long-term best-in-class medicine.
- Next-Generation Pipeline: 890 (next-gen VMAT2) expected to read out Phase 2 dose-finding data in mid-2027; designed for higher potency, no 2D6 metabolism, and reduced QT liability to facilitate LAI development.
- MDD Pipeline: Osevamator (AMPA PAM) has three Phase 3 studies scheduled for readout in H2 2027; distinct from ketamine by avoiding glutamatergic surges.
- Psychiatry Pipeline: Direclidine (schizophrenia) and Osvampitor (OSA) progressing to Phase 3 readouts in 2027.
Market and Competitive Landscape:
- TD market growing mid-teens annually due to rising antipsychotic prescriptions (75M prescriptions last year).
- Competition dynamics shifting in 2027 with competitor Teva utilizing IRA Maximum Fair Prices; Neurocrine avoids IRA impact until 2029.
- Chronicity faces potential entry from Vertex; management views competition as market-expanding but maintains superiority in reducing ACTH/androgens and early pediatric treatment.
- Psychedelics sector viewed as having unproven delivery paradigms; Neurocrine emphasizes Osevamator's superior tolerability and mechanism differentiation.
Risks and Challenges:
- IRA Pricing: 2029 price negotiations present the largest pricing risk, though management mitigates this with small biotech exemptions and expected growth post-negotiation.
- Clinical Trial Execution: High risk of failure in MDD trials due to placebo response; addressed via strict site oversight, 50/50 randomization, and limiting trial size (200 patients) while running three parallel trials.
- Competitive Disruption: Potential market dilution from Vertex's entry in CAH and future competitors in the VMAT2 space.
- Operational Complexity: Managing a portfolio of three distinct commercial products increases operational and strategic complexity compared to the previous single-product focus.
Management Commentary and Tone:
- CEO and management conveyed high confidence and "pragmatic optimism," emphasizing that uncertainty "error bars" regarding commercial trajectory for Ingresa (2027-2028) have narrowed.
- Tone reflects a strategic pivot from a single-product company to a diversified, financially robust biotech with a rich pipeline.
- Management explicitly stated they are not "working on flights" but were focused on strategic reflection, highlighting a disciplined, data-driven approach to R&D and commercialization.
Analyst Questions and Answers:
- IRA & Pricing: Clarified that 2027/2028 will see net revenue growth despite modest price concessions; 2029 is a "divot, not a cliff" with a manageable negotiation floor/ceiling.
- Long-Acting Injectables (LAIs): Confirmed unmet need for LAIs in TD; next-gen oral molecules (890) will precede LAI formulation, aiming for a dual oral/LAI regimen per patient.
- Chronicity vs. Vertex: Reiterated that Chronicity's upstream HPA axis control and ability to lower ACTH/androgens offer superior clinical outcomes and pediatric expansion opportunities not matched by competitors.
- MDD Strategy: Detailed specific operational mitigations for high placebo rates in MDD trials, including site monitoring and blinded data reviews to ensure high-quality data generation.
Other Key Points:
- Neurocrine is transitioning from a "one-medicine" to a "three-medicine" commercial model, diversifying revenue streams significantly.
- The company has secured strong payer access for Ingresa for 2027/2028, with access expected to remain stable despite IRA-related market changes.
- Clinical development for Osevamator includes ongoing safety data monitoring with a Data Safety Monitoring Board and no program changes due to safety concerns to date.
- Future growth strategy includes treating CAH patients as early as a few months old to alter disease trajectory and reduce long-term glucocorticoid exposure.
- Company
- NEUROCRINE BIOSCIENCES INC
- Keywords
- NEUROCRINE BIOSCIENCES INC